Biomarin Pharmaceutical

Yahoo Finance • 5 months ago

U.S. Food and Drug Administration Approves BioMarin's BRINEURA® (cerliponase alfa) for Children Under 3 Years with CLN2 Disease

Now Approved for Children of All Ages with CLN2 Batten Disease, Regardless of Whether They Yet Show Symptoms SAN RAFAEL, Calif., July 24, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the U.S. Food... Full story

Yahoo Finance • 8 months ago

4 Dominant Growth Stocks You'll Regret Not Buying in the New Nasdaq Bull Market

It's been a wild ride for investors since this decade began. Through each of the first four years, all three major stock indexes have traded off bear and bull markets, with the growth-fueled Nasdaq Composite(NASDAQINDEX: ^IXIC) enduring th... Full story

Yahoo Finance • 9 months ago

30 Biggest Biotechnology Companies in the World

In this article, we will be taking a look at the 30 biggest biotechnology companies in the world. If you do not want to learn about the global biotech market, head straight to the 5 Biggest Biotechnology Companies in the World. In the eve... Full story

Yahoo Finance • 10 months ago

UPDATE 2-BioMarin Pharma gets DOJ subpoena on sponsored testing programs for two therapies

(Adds company's comment in paragraphs 5 and 6) Feb 26 (Reuters) - BioMarin Pharmaceutical has received a subpoena from the U.S. Department of Justice seeking information about the company's sponsored testing programs related to two treatm... Full story

Yahoo Finance • 10 months ago

20 Fastest Growing Biotech Companies in the US

In this article, we will be taking a look at the 20 fastest growing biotech companies in the US. If you are not interested in learning about the landscape of biotech companies, head straight to the 5 Fastest Growing Biotech Companies In Th... Full story

Yahoo Finance • 10 months ago

BioMarin Reports Record Financial Results for the Fourth Quarter and Full-year 2023 and Provides Financial Guidance for 2024

Total FY'23 Revenues of $2.42 Billion (+15% Y/Y and +20% Y/Y at Constant Currency); GAAP Diluted Earnings per Share of $0.87 (+16% Y/Y) and Non-GAAP Diluted Earnings per Share of $2.08 (+36% Y/Y) VOXZOGO® Net Revenues of $146 Million in Q... Full story

Yahoo Finance • 11 months ago

Wall Street Analysts Just Trimmed Price Targets for These 10 Stocks

In this article, we will discuss the 10 stocks whose price targets were recently trimmed by analysts. If you want to see more such stocks on the list, go directly to Wall Street Analysts Just Trimmed Price Targets for These 5 Stocks. US s... Full story

Yahoo Finance • last year

Insider Sell: EVP, Chief Legal Officer George Davis Sells 13,764 Shares of Biomarin ...

Biomarin Pharmaceutical Inc (NASDAQ:BMRN), a global biotechnology company focused on developing and delivering therapies for rare genetic diseases, has recently witnessed a significant insider sell by one of its top executives. George Davi... Full story

Yahoo Finance • last year

Billionaire Louis Bacon’s 10 Stock Picks with Huge Upside Potential

In this article, we discuss billionaire Louis Bacon's 10 stock picks with huge upside potential. To skip the details about Mr. Bacon’s life, portfolio performance, and investment strategy, go directly to Billionaire Louis Bacon's 5 Stock P... Full story

Yahoo Finance • last year

Elfun Trusts Sheds Qualcomm in Q3, Embraces New Holdings

Insight into Elfun Trusts (Trades, Portfolio)' Latest Investment Moves and Portfolio Adjustments Warning! GuruFocus has detected 5 Warning Sign with MSFT. Elfun Trusts (Trades, Portfolio), a fund with exclusive access for General Electri... Full story

Yahoo Finance • last year

Top 20 Drug Companies in the US by Revenue

In this article, we will be taking a look at the top 20 drug companies in the US by revenue. To skip our detailed analysis, you can go directly to see the Top 5 Drug Companies in the US by Revenue. Following the Covid-19 pandemic, which d... Full story

Yahoo Finance • last year

BioMarin Surges As Activist Investor Elliott Reportedly Builds $1 Billion Stake

Activist investor Elliott has reportedly built a $1 billion stake in BioMarin Pharmaceutical, Reuters reported Tuesday as BMRN stock rocketed. Continue reading... Full story

Yahoo Finance • last year

4 Unique Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip

A 19% decline in the Nasdaq Composite over the past two years represents an ideal time for opportunistic long-term investors to go shopping for bargains. Continue reading... Full story

Yahoo Finance • last year

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Q3 2023 Earnings Call Transcript

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Q3 2023 Earnings Call Transcript November 1, 2023 BioMarin Pharmaceutical Inc. misses on earnings expectations. Reported EPS is $0.21 EPS, expectations were $0.46. Operator: Hello and welcome to... Full story

Yahoo Finance • last year

BioMarin Announces Strong Third Quarter 2023 Results, Including Continued Profitability, and 15% Total Revenue Growth Year Over Year

• Full-year 2023 Total Revenues and Earnings Per Share Financial Guidance Narrowed; VOXZOGO® and ROCTAVIAN® Net Product Revenue Guidance Adjusted for Full-year 2023 • VOXZOGO Now Approved for Children without Age Restrictions in the Unite... Full story

Yahoo Finance • last year

BioMarin Announces Retirement of Jean-Jacques Bienaimé; Appoints Alexander Hardy President and Chief Executive Officer

Mr. Hardy Brings More than 30 Years of Industry Experience, Most Recently as CEO of Genentech Mr. Bienaimé Served as CEO for 18 Years and as Chairman since 2015, Steering BioMarin to Profitability with Major Expansion of Commercial Portfo... Full story

Yahoo Finance • last year

Disney has a lot of challenges, going to take a while to turn around: Strategist

Walt Disney CEO Bob Iger may be staying on through 2026, but Thornburg Investment Management Co-Head of Investments Ben Kirby is still steering clear of the stock. "What is very clear is the consumer is slowing and Disney (DIS) is exposed... Full story

Yahoo Finance • last year

BioMarin to Host Second-Quarter 2023 Financial Results Conference Call and Webcast on Monday, July 31, at 4:30pm ET

SAN RAFAEL, Calif., July 12, 2023 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Monday,... Full story

Yahoo Finance • last year

Why Biotech Stocks Keep Falling on Good News

It’s a sign that investors are increasingly wary of the biopharma sector. It happened in late June, when Sarepta Therapeutics (ticker: SRPT) dropped 16% over the course of a few days after the FDA approved its new gene therapy for Duchenne... Full story

Yahoo Finance • 2 years ago

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Looks Inexpensive But Perhaps Not Attractive Enough

With a price-to-sales (or "P/S") ratio of 8.8x BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) may be sending bullish signals at the moment, given that almost half of all the Biotechs companies in the United States have P/S ratios greater than... Full story